CN112690386A - A dietetic composition with antioxidant and antibacterial effects and capable of enhancing cardiovascular and cerebrovascular and immunity - Google Patents
A dietetic composition with antioxidant and antibacterial effects and capable of enhancing cardiovascular and cerebrovascular and immunity Download PDFInfo
- Publication number
- CN112690386A CN112690386A CN202011408591.8A CN202011408591A CN112690386A CN 112690386 A CN112690386 A CN 112690386A CN 202011408591 A CN202011408591 A CN 202011408591A CN 112690386 A CN112690386 A CN 112690386A
- Authority
- CN
- China
- Prior art keywords
- extract
- parts
- powder
- blood
- functions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000036039 immunity Effects 0.000 title claims abstract description 26
- 230000002708 enhancing effect Effects 0.000 title claims abstract description 21
- 230000002526 effect on cardiovascular system Effects 0.000 title claims abstract description 19
- 239000003963 antioxidant agent Substances 0.000 title claims abstract description 15
- 230000003078 antioxidant effect Effects 0.000 title claims abstract description 14
- 230000000844 anti-bacterial effect Effects 0.000 title claims abstract description 8
- 235000005911 diet Nutrition 0.000 title claims description 13
- 239000000203 mixture Substances 0.000 title claims description 12
- 230000000378 dietary effect Effects 0.000 title claims description 6
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 74
- 229920001202 Inulin Polymers 0.000 claims abstract description 56
- 229940029339 inulin Drugs 0.000 claims abstract description 56
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims abstract description 54
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims abstract description 48
- 230000006870 function Effects 0.000 claims abstract description 46
- 235000010469 Glycine max Nutrition 0.000 claims abstract description 44
- PYMYPHUHKUWMLA-LMVFSUKVSA-N aldehydo-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims abstract description 41
- 244000068988 Glycine max Species 0.000 claims abstract description 40
- 239000000843 powder Substances 0.000 claims abstract description 39
- 241000282414 Homo sapiens Species 0.000 claims abstract description 38
- 229960003080 taurine Drugs 0.000 claims abstract description 37
- 239000000284 extract Substances 0.000 claims abstract description 34
- 244000130270 Fagopyrum tataricum Species 0.000 claims abstract description 33
- 235000014693 Fagopyrum tataricum Nutrition 0.000 claims abstract description 33
- 102000002068 Glycopeptides Human genes 0.000 claims abstract description 30
- 108010015899 Glycopeptides Proteins 0.000 claims abstract description 30
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims abstract description 30
- 235000013305 food Nutrition 0.000 claims abstract description 29
- SRBFZHDQGSBBOR-SOOFDHNKSA-N D-ribopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@@H]1O SRBFZHDQGSBBOR-SOOFDHNKSA-N 0.000 claims abstract description 26
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 claims abstract description 25
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims abstract description 23
- 229940107187 fructooligosaccharide Drugs 0.000 claims abstract description 23
- 240000001717 Vaccinium macrocarpon Species 0.000 claims abstract description 21
- 235000012545 Vaccinium macrocarpon Nutrition 0.000 claims abstract description 21
- 235000002118 Vaccinium oxycoccus Nutrition 0.000 claims abstract description 21
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims abstract description 21
- 235000004634 cranberry Nutrition 0.000 claims abstract description 21
- 229920001353 Dextrin Polymers 0.000 claims abstract description 20
- 239000004375 Dextrin Substances 0.000 claims abstract description 20
- 235000019425 dextrin Nutrition 0.000 claims abstract description 20
- 239000002994 raw material Substances 0.000 claims abstract description 19
- 108010038807 Oligopeptides Proteins 0.000 claims abstract description 18
- 102000015636 Oligopeptides Human genes 0.000 claims abstract description 18
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims abstract description 15
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims abstract description 14
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 14
- 241000233866 Fungi Species 0.000 claims abstract description 13
- 235000021388 linseed oil Nutrition 0.000 claims abstract description 13
- 239000000944 linseed oil Substances 0.000 claims abstract description 13
- 240000008042 Zea mays Species 0.000 claims abstract description 11
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims abstract description 11
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims abstract description 11
- 235000005822 corn Nutrition 0.000 claims abstract description 11
- 229920002774 Maltodextrin Polymers 0.000 claims abstract description 10
- 239000005913 Maltodextrin Substances 0.000 claims abstract description 10
- 235000020717 hawthorn extract Nutrition 0.000 claims abstract description 10
- 229940035034 maltodextrin Drugs 0.000 claims abstract description 10
- 239000003094 microcapsule Substances 0.000 claims abstract description 10
- 244000046146 Pueraria lobata Species 0.000 claims abstract description 9
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract description 9
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract description 9
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims abstract description 9
- 230000008455 cerebrovascular function Effects 0.000 claims abstract description 9
- 229910052711 selenium Inorganic materials 0.000 claims abstract description 9
- 239000011669 selenium Substances 0.000 claims abstract description 9
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 9
- 230000009084 cardiovascular function Effects 0.000 claims abstract description 8
- 239000003674 animal food additive Substances 0.000 claims abstract 3
- 230000002401 inhibitory effect Effects 0.000 claims description 17
- 241000894006 Bacteria Species 0.000 claims description 16
- -1 compound vitamin Chemical class 0.000 claims description 13
- 229940088594 vitamin Drugs 0.000 claims description 12
- 239000011782 vitamin Substances 0.000 claims description 12
- 235000013343 vitamin Nutrition 0.000 claims description 12
- 229930003231 vitamin Natural products 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 238000007254 oxidation reaction Methods 0.000 claims description 8
- 230000003385 bacteriostatic effect Effects 0.000 claims description 6
- 230000003647 oxidation Effects 0.000 claims description 6
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 4
- 241000190070 Sarracenia purpurea Species 0.000 claims description 3
- 239000008213 purified water Substances 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 230000036737 immune function Effects 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 abstract description 80
- 239000008280 blood Substances 0.000 abstract description 80
- 230000001965 increasing effect Effects 0.000 abstract description 26
- 208000024172 Cardiovascular disease Diseases 0.000 abstract description 18
- 239000003814 drug Substances 0.000 abstract description 15
- 208000026106 cerebrovascular disease Diseases 0.000 abstract description 14
- 230000036772 blood pressure Effects 0.000 abstract description 12
- 230000032683 aging Effects 0.000 abstract description 11
- 150000001875 compounds Chemical class 0.000 abstract description 10
- 201000010099 disease Diseases 0.000 abstract description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 9
- 230000035622 drinking Effects 0.000 abstract description 7
- 230000003064 anti-oxidating effect Effects 0.000 abstract description 5
- 235000013361 beverage Nutrition 0.000 abstract description 3
- 230000000694 effects Effects 0.000 description 67
- 230000001603 reducing effect Effects 0.000 description 47
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 35
- 230000003405 preventing effect Effects 0.000 description 32
- 235000000346 sugar Nutrition 0.000 description 32
- 235000019197 fats Nutrition 0.000 description 30
- 240000008620 Fagopyrum esculentum Species 0.000 description 20
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 20
- 238000010521 absorption reaction Methods 0.000 description 20
- 239000000047 product Substances 0.000 description 20
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 18
- 230000001737 promoting effect Effects 0.000 description 18
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 17
- 239000008103 glucose Substances 0.000 description 17
- 229930006000 Sucrose Natural products 0.000 description 16
- 235000012000 cholesterol Nutrition 0.000 description 16
- 239000000306 component Substances 0.000 description 16
- 210000001035 gastrointestinal tract Anatomy 0.000 description 16
- 229920001542 oligosaccharide Polymers 0.000 description 16
- 239000005720 sucrose Substances 0.000 description 16
- 229960004793 sucrose Drugs 0.000 description 16
- IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 description 15
- 206010010774 Constipation Diseases 0.000 description 14
- 150000002632 lipids Chemical class 0.000 description 14
- 206010012601 diabetes mellitus Diseases 0.000 description 13
- 230000012010 growth Effects 0.000 description 13
- 210000000936 intestine Anatomy 0.000 description 13
- 241000186000 Bifidobacterium Species 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 12
- 210000004556 brain Anatomy 0.000 description 12
- 230000000968 intestinal effect Effects 0.000 description 12
- 150000002482 oligosaccharides Chemical class 0.000 description 12
- 238000011160 research Methods 0.000 description 12
- 235000006708 antioxidants Nutrition 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 11
- 238000011161 development Methods 0.000 description 11
- 230000018109 developmental process Effects 0.000 description 11
- 238000000855 fermentation Methods 0.000 description 11
- 230000004151 fermentation Effects 0.000 description 11
- 210000004185 liver Anatomy 0.000 description 11
- 230000001105 regulatory effect Effects 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- 206010028980 Neoplasm Diseases 0.000 description 10
- 241000700159 Rattus Species 0.000 description 10
- 230000009286 beneficial effect Effects 0.000 description 10
- 210000004204 blood vessel Anatomy 0.000 description 10
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 10
- 210000002429 large intestine Anatomy 0.000 description 10
- 210000003205 muscle Anatomy 0.000 description 10
- 235000013406 prebiotics Nutrition 0.000 description 10
- 230000035755 proliferation Effects 0.000 description 10
- 210000001072 colon Anatomy 0.000 description 9
- 230000002107 myocardial effect Effects 0.000 description 9
- 150000003254 radicals Chemical class 0.000 description 9
- 210000002784 stomach Anatomy 0.000 description 9
- 241001092040 Crataegus Species 0.000 description 8
- 230000002354 daily effect Effects 0.000 description 8
- 230000029087 digestion Effects 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 150000004676 glycans Chemical class 0.000 description 8
- 230000036541 health Effects 0.000 description 8
- 210000002216 heart Anatomy 0.000 description 8
- 235000016709 nutrition Nutrition 0.000 description 8
- 229920001282 polysaccharide Polymers 0.000 description 8
- 239000005017 polysaccharide Substances 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 8
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 7
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 7
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 7
- 208000007536 Thrombosis Diseases 0.000 description 7
- 230000037213 diet Effects 0.000 description 7
- 230000007937 eating Effects 0.000 description 7
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 7
- 230000004060 metabolic process Effects 0.000 description 7
- 210000000813 small intestine Anatomy 0.000 description 7
- 241000271566 Aves Species 0.000 description 6
- 235000009917 Crataegus X brevipes Nutrition 0.000 description 6
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 description 6
- 235000009685 Crataegus X maligna Nutrition 0.000 description 6
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 description 6
- 235000009486 Crataegus bullatus Nutrition 0.000 description 6
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 description 6
- 235000009682 Crataegus limnophila Nutrition 0.000 description 6
- 235000004423 Crataegus monogyna Nutrition 0.000 description 6
- 235000002313 Crataegus paludosa Nutrition 0.000 description 6
- 235000009840 Crataegus x incaedua Nutrition 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 6
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 6
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 6
- 230000017531 blood circulation Effects 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 230000013872 defecation Effects 0.000 description 6
- 235000013325 dietary fiber Nutrition 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 210000003743 erythrocyte Anatomy 0.000 description 6
- 229930003935 flavonoid Natural products 0.000 description 6
- 150000002215 flavonoids Chemical class 0.000 description 6
- 235000017173 flavonoids Nutrition 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 210000002569 neuron Anatomy 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 150000004666 short chain fatty acids Chemical class 0.000 description 6
- 235000021391 short chain fatty acids Nutrition 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 208000031226 Hyperlipidaemia Diseases 0.000 description 5
- 102000004877 Insulin Human genes 0.000 description 5
- 108090001061 Insulin Proteins 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 5
- 206010039966 Senile dementia Diseases 0.000 description 5
- 230000000747 cardiac effect Effects 0.000 description 5
- 201000001421 hyperglycemia Diseases 0.000 description 5
- 230000001976 improved effect Effects 0.000 description 5
- 229910052500 inorganic mineral Inorganic materials 0.000 description 5
- 229940125396 insulin Drugs 0.000 description 5
- 239000011707 mineral Substances 0.000 description 5
- 235000010755 mineral Nutrition 0.000 description 5
- 208000031225 myocardial ischemia Diseases 0.000 description 5
- 230000008855 peristalsis Effects 0.000 description 5
- 230000035790 physiological processes and functions Effects 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 210000002027 skeletal muscle Anatomy 0.000 description 5
- 239000013589 supplement Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 235000019640 taste Nutrition 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- 239000003053 toxin Substances 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 201000001320 Atherosclerosis Diseases 0.000 description 4
- 208000002177 Cataract Diseases 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 4
- 229920002527 Glycogen Polymers 0.000 description 4
- 240000008892 Helianthus tuberosus Species 0.000 description 4
- 235000003230 Helianthus tuberosus Nutrition 0.000 description 4
- 206010020751 Hypersensitivity Diseases 0.000 description 4
- 108010028554 LDL Cholesterol Proteins 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 208000008589 Obesity Diseases 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 208000006673 asthma Diseases 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 235000004426 flaxseed Nutrition 0.000 description 4
- 235000013312 flour Nutrition 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- 229940096919 glycogen Drugs 0.000 description 4
- 208000006454 hepatitis Diseases 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 230000003871 intestinal function Effects 0.000 description 4
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 229910021645 metal ion Inorganic materials 0.000 description 4
- 210000004165 myocardium Anatomy 0.000 description 4
- 210000005036 nerve Anatomy 0.000 description 4
- 239000002858 neurotransmitter agent Substances 0.000 description 4
- 230000035764 nutrition Effects 0.000 description 4
- 235000020824 obesity Nutrition 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000001850 reproductive effect Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
- DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 description 4
- 231100000765 toxin Toxicity 0.000 description 4
- 241000221377 Auricularia Species 0.000 description 3
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- 241000657480 Crataegus pinnatifida Species 0.000 description 3
- 235000017159 Crataegus pinnatifida Nutrition 0.000 description 3
- 102000005915 GABA Receptors Human genes 0.000 description 3
- 108010005551 GABA Receptors Proteins 0.000 description 3
- 108010023302 HDL Cholesterol Proteins 0.000 description 3
- 241000590002 Helicobacter pylori Species 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 240000006240 Linum usitatissimum Species 0.000 description 3
- 235000004431 Linum usitatissimum Nutrition 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- 206010036618 Premenstrual syndrome Diseases 0.000 description 3
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 3
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 208000007107 Stomach Ulcer Diseases 0.000 description 3
- 241000209140 Triticum Species 0.000 description 3
- 235000021307 Triticum Nutrition 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 3
- 206010003119 arrhythmia Diseases 0.000 description 3
- 230000006793 arrhythmia Effects 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000003613 bile acid Substances 0.000 description 3
- 229940093797 bioflavonoids Drugs 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 230000000112 colonic effect Effects 0.000 description 3
- 210000004351 coronary vessel Anatomy 0.000 description 3
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N daidzein Chemical compound C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 201000005917 gastric ulcer Diseases 0.000 description 3
- 229940037467 helicobacter pylori Drugs 0.000 description 3
- 235000020256 human milk Nutrition 0.000 description 3
- 210000004251 human milk Anatomy 0.000 description 3
- 230000002218 hypoglycaemic effect Effects 0.000 description 3
- 229910052742 iron Inorganic materials 0.000 description 3
- 229960004488 linolenic acid Drugs 0.000 description 3
- 230000003859 lipid peroxidation Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 230000004089 microcirculation Effects 0.000 description 3
- 150000002772 monosaccharides Chemical class 0.000 description 3
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 3
- 210000001087 myotubule Anatomy 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 230000003204 osmotic effect Effects 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 235000005875 quercetin Nutrition 0.000 description 3
- 229960001285 quercetin Drugs 0.000 description 3
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 3
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 3
- 235000005493 rutin Nutrition 0.000 description 3
- 229960004555 rutoside Drugs 0.000 description 3
- 230000002000 scavenging effect Effects 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 208000019206 urinary tract infection Diseases 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- ZTOJFFHGPLIVKC-YAFCTCPESA-N (2e)-3-ethyl-2-[(z)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound S\1C2=CC(S(O)(=O)=O)=CC=C2N(CC)C/1=N/N=C1/SC2=CC(S(O)(=O)=O)=CC=C2N1CC ZTOJFFHGPLIVKC-YAFCTCPESA-N 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical group C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 2
- FFRBMBIXVSCUFS-UHFFFAOYSA-N 2,4-dinitro-1-naphthol Chemical compound C1=CC=C2C(O)=C([N+]([O-])=O)C=C([N+]([O-])=O)C2=C1 FFRBMBIXVSCUFS-UHFFFAOYSA-N 0.000 description 2
- 108010011619 6-Phytase Proteins 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000186016 Bifidobacterium bifidum Species 0.000 description 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 208000001378 Carbon Tetrachloride Poisoning Diseases 0.000 description 2
- 108010062745 Chloride Channels Proteins 0.000 description 2
- 102000011045 Chloride Channels Human genes 0.000 description 2
- 101000862089 Clarkia lewisii Glucose-6-phosphate isomerase, cytosolic 1A Proteins 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 235000014493 Crataegus Nutrition 0.000 description 2
- 244000248416 Fagopyrum cymosum Species 0.000 description 2
- 208000004930 Fatty Liver Diseases 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 229920002670 Fructan Polymers 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- 101710129448 Glucose-6-phosphate isomerase 2 Proteins 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- 102000015779 HDL Lipoproteins Human genes 0.000 description 2
- 206010019708 Hepatic steatosis Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 208000013016 Hypoglycemia Diseases 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 102000003746 Insulin Receptor Human genes 0.000 description 2
- 108010001127 Insulin Receptor Proteins 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 2
- YXOLAZRVSSWPPT-UHFFFAOYSA-N Morin Chemical compound OC1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 YXOLAZRVSSWPPT-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 101710184309 Probable sucrose-6-phosphate hydrolase Proteins 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 235000004789 Rosa xanthina Nutrition 0.000 description 2
- 241000220222 Rosaceae Species 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 102400000472 Sucrase Human genes 0.000 description 2
- 101710112652 Sucrose-6-phosphate hydrolase Proteins 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- WBWWGRHZICKQGZ-UHFFFAOYSA-N Taurocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)C(O)C2 WBWWGRHZICKQGZ-UHFFFAOYSA-N 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 244000291414 Vaccinium oxycoccus Species 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 210000000579 abdominal fat Anatomy 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 229960005305 adenosine Drugs 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 108010028144 alpha-Glucosidases Proteins 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 230000004531 blood pressure lowering effect Effects 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 230000032677 cell aging Effects 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 description 2
- 235000021019 cranberries Nutrition 0.000 description 2
- 230000001934 delay Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 230000003467 diminishing effect Effects 0.000 description 2
- 150000002016 disaccharides Chemical class 0.000 description 2
- 239000000386 donor Substances 0.000 description 2
- 210000005069 ears Anatomy 0.000 description 2
- 238000005265 energy consumption Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 208000010706 fatty liver disease Diseases 0.000 description 2
- 235000021050 feed intake Nutrition 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- BJHIKXHVCXFQLS-UYFOZJQFSA-N fructose group Chemical group OCC(=O)[C@@H](O)[C@H](O)[C@H](O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 description 2
- 239000000446 fuel Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 230000007661 gastrointestinal function Effects 0.000 description 2
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 230000034659 glycolysis Effects 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 230000004217 heart function Effects 0.000 description 2
- 231100000753 hepatic injury Toxicity 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000007413 intestinal health Effects 0.000 description 2
- 210000004347 intestinal mucosa Anatomy 0.000 description 2
- 235000011073 invertase Nutrition 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 230000005923 long-lasting effect Effects 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000002398 materia medica Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 210000000110 microvilli Anatomy 0.000 description 2
- 235000007708 morin Nutrition 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 230000004693 neuron damage Effects 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 230000036284 oxygen consumption Effects 0.000 description 2
- 230000000242 pagocytic effect Effects 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 229940085127 phytase Drugs 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 230000002028 premature Effects 0.000 description 2
- KAQKFAOMNZTLHT-OZUDYXHBSA-N prostaglandin I2 Chemical compound O1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-OZUDYXHBSA-N 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 229940079877 pyrogallol Drugs 0.000 description 2
- 210000001139 rectus abdominis Anatomy 0.000 description 2
- 230000002040 relaxant effect Effects 0.000 description 2
- 230000033764 rhythmic process Effects 0.000 description 2
- 229920002477 rna polymer Polymers 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 235000019605 sweet taste sensations Nutrition 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- WBWWGRHZICKQGZ-GIHLXUJPSA-N taurocholic acid Chemical compound C([C@@H]1C[C@H]2O)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@H](O)C1 WBWWGRHZICKQGZ-GIHLXUJPSA-N 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 230000002936 tranquilizing effect Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 230000001228 trophic effect Effects 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 208000019553 vascular disease Diseases 0.000 description 2
- 230000001457 vasomotor Effects 0.000 description 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- MJYQFWSXKFLTAY-OVEQLNGDSA-N (2r,3r)-2,3-bis[(4-hydroxy-3-methoxyphenyl)methyl]butane-1,4-diol;(2r,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O.C1=C(O)C(OC)=CC(C[C@@H](CO)[C@H](CO)CC=2C=C(OC)C(O)=CC=2)=C1 MJYQFWSXKFLTAY-OVEQLNGDSA-N 0.000 description 1
- ZFTFOHBYVDOAMH-XNOIKFDKSA-N (2r,3s,4s,5r)-5-[[(2r,3s,4s,5r)-5-[[(2r,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-2-(hydroxymethyl)oxolan-2-yl]oxymethyl]-2-(hydroxymethyl)oxolane-2,3,4-triol Chemical class O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@@H]1[C@@H](O)[C@H](O)[C@](CO)(OC[C@@H]2[C@H]([C@H](O)[C@@](O)(CO)O2)O)O1 ZFTFOHBYVDOAMH-XNOIKFDKSA-N 0.000 description 1
- STMUIVWQDNMZCA-CRKDRTNXSA-N (2s,3r,4s,5r)-2-(6-aminopurin-9-yl)-2-fluoro-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@]1(F)O[C@H](CO)[C@@H](O)[C@H]1O STMUIVWQDNMZCA-CRKDRTNXSA-N 0.000 description 1
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
- IQZWKGWOBPJWMX-UHFFFAOYSA-N 2-Methyladenosine Natural products C12=NC(C)=NC(N)=C2N=CN1C1OC(CO)C(O)C1O IQZWKGWOBPJWMX-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 1
- IQZWKGWOBPJWMX-IOSLPCCCSA-N 2-methyladenosine Chemical compound C12=NC(C)=NC(N)=C2N=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O IQZWKGWOBPJWMX-IOSLPCCCSA-N 0.000 description 1
- QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 1
- ADVPTQAUNPRNPO-REOHCLBHSA-M 3-sulfino-L-alanine(1-) Chemical compound [O-]C(=O)[C@@H]([NH3+])CS([O-])=O ADVPTQAUNPRNPO-REOHCLBHSA-M 0.000 description 1
- ZOLBALGTFCCTJF-UHFFFAOYSA-N 4-[1-hydroxy-2-(propan-2-ylamino)ethyl]benzene-1,2-diol;sulfuric acid Chemical compound OS(O)(=O)=O.CC(C)NCC(O)C1=CC=C(O)C(O)=C1.CC(C)NCC(O)C1=CC=C(O)C(O)=C1 ZOLBALGTFCCTJF-UHFFFAOYSA-N 0.000 description 1
- ODEHMIGXGLNAKK-OESPXIITSA-N 6-kestotriose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@@H]1[C@@H](O)[C@H](O)[C@](CO)(O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1 ODEHMIGXGLNAKK-OESPXIITSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 230000002407 ATP formation Effects 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 206010059245 Angiopathy Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 244000286893 Aspalathus contaminatus Species 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 241000606125 Bacteroides Species 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 241000208671 Campanulaceae Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 1
- 244000298479 Cichorium intybus Species 0.000 description 1
- 235000007542 Cichorium intybus Nutrition 0.000 description 1
- 241000729173 Cirsium japonicum Species 0.000 description 1
- 241000193468 Clostridium perfringens Species 0.000 description 1
- 208000009084 Cold Injury Diseases 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
- RFSUNEUAIZKAJO-VRPWFDPXSA-N D-Fructose Natural products OC[C@H]1OC(O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-VRPWFDPXSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 1
- GMTUGPYJRUMVTC-UHFFFAOYSA-N Daidzin Natural products OC(COc1ccc2C(=O)C(=COc2c1)c3ccc(O)cc3)C(O)C(O)C(O)C=O GMTUGPYJRUMVTC-UHFFFAOYSA-N 0.000 description 1
- KYQZWONCHDNPDP-UHFFFAOYSA-N Daidzoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-UHFFFAOYSA-N 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 235000010852 Fagopyrum cymosum Nutrition 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 241001071804 Gentianaceae Species 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 206010019133 Hangover Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010019375 Helicobacter infections Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 206010023232 Joint swelling Diseases 0.000 description 1
- SHZGCJCMOBCMKK-PQMKYFCFSA-N L-Fucose Natural products C[C@H]1O[C@H](O)[C@@H](O)[C@@H](O)[C@@H]1O SHZGCJCMOBCMKK-PQMKYFCFSA-N 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 241000234280 Liliaceae Species 0.000 description 1
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 241000736262 Microbiota Species 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- FLDFNEBHEXLZRX-DLQNOBSRSA-N Nystose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(O[C@@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 FLDFNEBHEXLZRX-DLQNOBSRSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 208000005141 Otitis Diseases 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 240000005001 Paeonia suffruticosa Species 0.000 description 1
- 235000003889 Paeonia suffruticosa Nutrition 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 1
- 108010064851 Plant Proteins Proteins 0.000 description 1
- 241000209504 Poaceae Species 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 235000011552 Rhamnus crocea Nutrition 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 244000300264 Spinacia oleracea Species 0.000 description 1
- 235000009337 Spinacia oleracea Nutrition 0.000 description 1
- 206010058339 Splenitis Diseases 0.000 description 1
- 241000194019 Streptococcus mutans Species 0.000 description 1
- 241001415849 Strigiformes Species 0.000 description 1
- 206010061373 Sudden Hearing Loss Diseases 0.000 description 1
- 208000000491 Tendinopathy Diseases 0.000 description 1
- 206010043255 Tendonitis Diseases 0.000 description 1
- 235000006468 Thea sinensis Nutrition 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 241000759263 Ventia crocea Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 231100000354 acute hepatitis Toxicity 0.000 description 1
- 229960001570 ademetionine Drugs 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- PYMYPHUHKUWMLA-VAYJURFESA-N aldehydo-L-arabinose Chemical compound OC[C@H](O)[C@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-VAYJURFESA-N 0.000 description 1
- 150000001320 aldopentoses Chemical class 0.000 description 1
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 230000037354 amino acid metabolism Effects 0.000 description 1
- 229940124277 aminobutyric acid Drugs 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 206010003230 arteritis Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000007698 birth defect Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 235000020279 black tea Nutrition 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 208000024330 bloating Diseases 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000007177 brain activity Effects 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 230000004641 brain development Effects 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 235000015496 breakfast cereal Nutrition 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 210000001627 cerebral artery Anatomy 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000002595 cold damage Effects 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 229930003836 cresol Natural products 0.000 description 1
- 235000019784 crude fat Nutrition 0.000 description 1
- 210000001100 crypt cell Anatomy 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 235000007240 daidzein Nutrition 0.000 description 1
- KYQZWONCHDNPDP-QNDFHXLGSA-N daidzein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-QNDFHXLGSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 1
- 229940090949 docosahexaenoic acid Drugs 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 208000019258 ear infection Diseases 0.000 description 1
- 230000009982 effect on human Effects 0.000 description 1
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 1
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 1
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000003617 erythrocyte membrane Anatomy 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005428 food component Substances 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 1
- 150000003271 galactooligosaccharides Chemical class 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 230000002414 glycolytic effect Effects 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 230000002650 habitual effect Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 230000037219 healthy weight Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 244000005702 human microbiome Species 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 239000000852 hydrogen donor Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000002102 hyperpolarization Effects 0.000 description 1
- 239000000960 hypophysis hormone Substances 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 208000009326 ileitis Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 108010090785 inulinase Proteins 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 208000023589 ischemic disease Diseases 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 229940039009 isoproterenol Drugs 0.000 description 1
- 229940018435 isoproterenol sulfate Drugs 0.000 description 1
- 235000008777 kaempferol Nutrition 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- 229940118019 malondialdehyde Drugs 0.000 description 1
- 201000003995 melancholia Diseases 0.000 description 1
- 230000007087 memory ability Effects 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 239000002366 mineral element Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 208000015001 muscle soreness Diseases 0.000 description 1
- 230000017311 musculoskeletal movement, spinal reflex action Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 230000007830 nerve conduction Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- XKLJHFLUAHKGGU-UHFFFAOYSA-N nitrous amide Chemical compound ON=N XKLJHFLUAHKGGU-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 235000015816 nutrient absorption Nutrition 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- FLDFNEBHEXLZRX-UHFFFAOYSA-N nystose Natural products OC1C(O)C(CO)OC1(CO)OCC1(OCC2(OC3C(C(O)C(O)C(CO)O3)O)C(C(O)C(CO)O2)O)C(O)C(O)C(CO)O1 FLDFNEBHEXLZRX-UHFFFAOYSA-N 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000004203 pancreatic function Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000001297 phlebitis Diseases 0.000 description 1
- 235000002949 phytic acid Nutrition 0.000 description 1
- 229940068041 phytic acid Drugs 0.000 description 1
- 239000000467 phytic acid Substances 0.000 description 1
- 235000021118 plant-derived protein Nutrition 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000021395 porridge Nutrition 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 description 1
- 210000001147 pulmonary artery Anatomy 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 230000004283 retinal dysfunction Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000005808 skin problem Effects 0.000 description 1
- 210000001189 slow twitch fiber Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 201000004415 tendinitis Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000004753 textile Substances 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 102000014898 transaminase activity proteins Human genes 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 210000003854 type 2 muscle cell Anatomy 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000004382 visual function Effects 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Botany (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a food therapy formula with antioxidant and antibacterial effects and capable of enhancing cardiovascular and cerebrovascular functions and human body immunity, which comprises the following components: the feed additive comprises soybean glycopeptide, resistant dextrin, maltodextrin, inulin, fructo-oligosaccharide, linseed oil microcapsule powder, corn oligopeptide powder, black fungus extract, kudzu root extract, hawthorn extract, tartary buckwheat extract, cranberry fruit powder, gamma-aminobutyric acid, D-ribose, L-arabinose, taurine, selenium-enriched yeast powder and multivitamin. The compound formula product takes various soybean glycopeptides as a main raw material, is matched with various natural pure traditional Chinese medicine components for assistance, not only can effectively reduce blood pressure and blood fat, but also can well improve the immunity of a human body through antioxidation and bacteriostasis, has the functions of effectively resisting aging and delaying aging time, and particularly can inhibit or reduce diseases caused by cardiovascular and cerebrovascular diseases through increasing the functions of the cardiovascular and cerebrovascular diseases. Is a general compound beverage product suitable for common drinking.
Description
Technical Field
The invention relates to the field of health-care food, in particular to a food therapy formula which has antioxidant and antibacterial effects and can enhance cardiovascular and cerebrovascular functions and human body immunity.
Background
With the development of society, especially the progress of science and technology, the rapid development of social productivity is greatly promoted, and the life of people is greatly improved and enhanced. The fast paced life makes people enjoy increasingly abundant physical life, and brings more and more health diseases caused by irregular life and unreasonable dietary structure, so that reasonable diet, enhancement of human immunity and improvement of health indexes become more and more people concerned.
With fast-paced work and life, unreasonable dietary structure and irregular working time, the sub-health performance of the body is more and more younger, wherein the cardiovascular and cerebrovascular diseases are more prominent, and although the whole life of people is prolonged, the sub-health state such as low immunity and the like is solved by medicines and the like, which is not scientific.
Cardiovascular and cerebrovascular diseases are the general names of cardiovascular and cerebrovascular diseases, and generally refer to ischemic or hemorrhagic diseases of heart, brain and systemic tissues caused by hyperlipidemia, blood viscosity, atherosclerosis, hypertension and the like. The cardiovascular and cerebrovascular diseases are common diseases seriously threatening the health of human beings, particularly the middle-aged and old people over 50 years old, and have the characteristics of high morbidity, high disability rate and high mortality, even if the most advanced and perfect treatment means at present are applied, more than 50 percent of cerebrovascular accident survivors still can not completely self-care, the number of people dying from the cardiovascular and cerebrovascular diseases in each year in the world reaches 1500 ten thousands, the people live at the first of various causes of death, and the diseased groups slowly have the regional young trend.
The soybean glycopeptide is a compound formed by combining soybean oligosaccharide and soybean oligopeptide according to a certain proportion by an enzyme process. Is yellow to light yellow solid powder and is easy to absorb moisture. The soybean oligopeptide and the soybean oligosaccharide have small molecular weight, can be completely dissolved in water, and the water solution is golden yellow clear transparent liquid. No beany flavor, good taste, acid-base stability and good fluidity. Has good physiological function, and is embodied in the following aspects: 1. it can be absorbed rapidly without digestion. The soybean oligopeptide and the soybean oligosaccharide have small molecular weight and can quickly enter blood to play a role without digestion. Pharmacokinetics shows that the soybean glycopeptide enters blood 5min after oral administration, and starts to exert efficacy 15min later, and the half-life period is 12 h. 2. Has good function of regulating blood fat. Experiments show that the traditional Chinese medicine composition can obviously reduce TC, TG and LDL-C of rat serum with hyperlipidemia, increase HDL-C and improve blood fat level. Has important significance for preventing and treating hyperlipidemia and cardiovascular diseases. 3. Has the function of influencing the generation of active substances in blood vessels. Experiments prove that the composition can increase PGI2 and NO and reduce the ratio of TXA2 to TXA2/PGI 2. Preventing lipid peroxidation, reducing thrombosis, maintaining normal vasomotor function, and resisting atherosclerosis. 4. Improving hemorheology. Improving erythrocyte deformability, reducing erythrocyte aggregation, changing blood viscosity, reducing whole blood and plasma viscosity, preventing blood lipid deposition on aortic wall, recovering erythrocyte rigidity index, removing lipid plaque deposited on vascular wall, and recovering blood vessel elasticity. 5. And (4) antioxidation function. The glycopeptide has good effect of eliminating H, O, DPPH free radical, ABTS, lipid peroxide intermediate free radical and the like, inhibits the auto-oxidation of pyrogallol, and effectively delays the process of cell aging. 6. Increasing the immunity of the organism. The soybean glycopeptide can remarkably improve T lymphocyte transformation, macrophage phagocytic ability, E-rosette formation, Nk natural killer cell and plasma immunoglobulin content of a mouse. 7. Enhancing physical strength and relieving fatigue. The soybean glycopeptide can obviously increase the content of liver glycogen and muscle glycogen in the animal body, and has obvious physical enhancement effect. 8. Reducing blood sugar, and preventing and treating diabetes. The soybean glycopeptide can slowly inhibit the alpha-glucosidase on intestinal microvilli from decomposing glucose in a glucose donor, thereby achieving the effects of reducing blood sugar and assisting in preventing and treating diabetes. 9. Regulating intestinal function, and preventing and treating constipation. The oligosaccharide in the soybean glycopeptide is not absorbed by human body, but can promote proliferation and growth of Bacillus bifidus in large intestine, secrete health promoting vitamins and microelements, inhibit proliferation of harmful bacteria and secretion of harmful substances, increase large intestine peristalsis, and promote defecation. Although both soy oligosaccharides and soy oligopeptides have several functions as described above, the combination of the two is more effective than the single use, especially in improving blood regulation.
Therefore, the problem of providing a formula product which can rely on the soybean glycopeptide as a main raw material and further can provide multiple complex nutritional ingredients required by the human body is worthy of research.
Disclosure of Invention
In order to solve the defects in the prior art, the invention provides a food therapy formula which has antioxidant and antibacterial effects and can enhance cardiovascular and cerebrovascular functions and human body immunity.
The purpose of the invention is realized as follows:
a dietetic therapy formula with antioxidant and antibacterial effects and capable of enhancing cardiovascular and cerebrovascular and human body immunity functions comprises the following components:
soybean glycopeptide, resistant dextrin, maltodextrin, inulin, fructo-oligosaccharide, linseed oil microcapsule powder, corn oligopeptide powder, black fungus extract, kudzu root extract, hawthorn extract, tartary buckwheat extract, cranberry fruit powder, gamma-aminobutyric acid, D-ribose, L-arabinose, taurine, selenium-enriched yeast powder and multivitamin;
the weight percentages of the components are as follows: 15-25 parts of soybean glycopeptide, 16-24 parts of resistant dextrin, 16-22 parts of maltodextrin, 12-18 parts of inulin, 8-12 parts of fructo-oligosaccharide, 3-4 parts of linseed oil microcapsule powder, 0.5-0.8 part of corn oligopeptide powder, 0.5-0.8 part of black fungus extract, 0.5-0.8 part of kudzu root extract, 0.45-0.8 part of hawthorn extract, 0.4-0.8 part of tartary buckwheat extract, 3-7 parts of cranberry fruit powder, 0.1-0.3 part of gamma-aminobutyric acid, 0.2-0.4 part of D-ribose, 0.5-1 part of L-arabinose, 0.1 part of taurine, 0.1 part of selenium-enriched yeast and 0.39 part of compound vitamin, wherein the sum of the raw material components is one hundred percent;
the weight percentages of the components are as follows: soybean glycopeptide 20, resistant dextrin 20, maltodextrin 20, inulin 16, fructo-oligosaccharide 10, linseed oil microcapsule powder 2.19, corn oligopeptide powder 0.78, black fungus extract 0.78, kudzu root extract 0.78, hawthorn extract 0.78, tartary buckwheat extract 0.78, cranberry fruit powder 6.33, gamma-aminobutyric acid 0.2, D-ribose 0.39, L-arabinose 0.8, taurine 0.1, selenium-enriched yeast 0.1 and vitamin complex 0.39, wherein the sum of the raw material components is one hundred percent;
the preparation method comprises the following steps: preparing the raw materials according to the percentage, then pouring the purified water into a water cup, sequentially adding the raw materials into the cup, and uniformly stirring.
Has the positive and beneficial effects that: the invention discloses a food therapy formula with antioxidant and bacteriostatic effects and capable of enhancing cardiovascular and cerebrovascular functions and human body immunity, which is a compound formula product, takes a plurality of soybean glycopeptides as main raw materials, is matched with a plurality of natural pure traditional Chinese medicine components for auxiliary use, not only can effectively reduce blood pressure and blood fat, but also can well improve human body immunity through antioxidant and bacteriostatic effects, plays the roles of effectively resisting aging and delaying aging time, and particularly can inhibit or reduce diseases caused by cardiovascular and cerebrovascular diseases through increasing the functions of the cardiovascular and cerebrovascular diseases. Is a general compound beverage product suitable for common drinking.
Detailed Description
The invention will be further described with reference to specific examples:
example 1
A soybean glycopeptide compound formula with the functions of delaying senility and enhancing the immunity of a human body comprises the following components in percentage by mass: 25 parts of soybean glycopeptide, 20 parts of resistant dextrin, 20 parts of maltodextrin, 12 parts of inulin, 10 parts of fructo-oligosaccharide, 3 parts of linseed oil microcapsule powder, 0.5 part of corn oligopeptide powder, 0.5 part of black fungus extract, 0.5 part of kudzu root extract, 0.8 part of hawthorn extract, 0.5 part of tartary buckwheat extract, 3 parts of cranberry fruit powder, 0.3 part of gamma-aminobutyric acid, 0.2 part of D-ribose, 1 part of L-arabinose, 0.1 part of taurine, 0.1 part of selenium-enriched yeast and 0.5 part of vitamin complex, wherein the sum of the raw material components accounts for one hundred percent;
example 2
A soybean glycopeptide compound formula with the functions of delaying senility and enhancing the immunity of a human body comprises the following components in percentage by mass: soybean glycopeptide 20, resistant dextrin 20, maltodextrin 20, inulin 16, fructo-oligosaccharide 10, linseed oil microcapsule powder 2.19, corn oligopeptide powder 0.78, black fungus extract 0.78, kudzu root extract 0.78, hawthorn extract 0.78, tartary buckwheat extract 0.78, cranberry fruit powder 6.33, gamma-aminobutyric acid 0.2, D-ribose 0.39, L-arabinose 0.8, taurine 0.1, selenium-enriched yeast 0.1 and vitamin complex 0.39, wherein the sum of the raw material components is one hundred percent;
the preparation method comprises the following steps: preparing the raw materials according to the percentage, then pouring the purified water into a water cup, sequentially adding the raw materials into the cup, and uniformly stirring.
And (3) analyzing the material composition mechanism:
and (3) soybean glycopeptide: the soybean glycopeptide is a compound formed by combining soybean oligosaccharide and soybean oligopeptide according to a certain proportion by an enzyme process. Is yellow to light yellow solid powder and is easy to absorb moisture. The soybean oligopeptide and the soybean oligosaccharide have small molecular weight, can be completely dissolved in water, and the water solution is golden yellow clear transparent liquid. No beany flavor, good taste, acid-base stability and good fluidity. Has good physiological function, and is embodied in the following aspects: 1. it can be absorbed rapidly without digestion. The soybean oligopeptide and the soybean oligosaccharide have small molecular weight and can quickly enter blood to play a role without digestion. Pharmacokinetics shows that the soybean glycopeptide enters blood 5min after oral administration, and starts to exert efficacy 15min later, and the half-life period is 12 h. 2. Has good function of regulating blood fat. Experiments show that the traditional Chinese medicine composition can obviously reduce TC, TG and LDL-C of rat serum with hyperlipidemia, increase HDL-C and improve blood fat level. Has important significance for preventing and treating hyperlipidemia and cardiovascular diseases. 3. Has the function of influencing the generation of active substances in blood vessels. Experiments prove that the composition can increase PGI2 and NO and reduce the ratio of TXA2 to TXA2/PGI 2. Preventing lipid peroxidation, reducing thrombosis, maintaining normal vasomotor function, and resisting atherosclerosis. 4. Improving hemorheology. Improving erythrocyte deformability, reducing erythrocyte aggregation, changing blood viscosity, reducing whole blood and plasma viscosity, preventing blood lipid deposition on aortic wall, recovering erythrocyte rigidity index, removing lipid plaque deposited on vascular wall, and recovering blood vessel elasticity. 5. And (4) antioxidation function. The glycopeptide has good effect of eliminating H, O, DPPH free radical, ABTS, lipid peroxide intermediate free radical and the like, inhibits the auto-oxidation of pyrogallol, and effectively delays the process of cell aging. 6. Increasing the immunity of the organism. The soybean glycopeptide can remarkably improve T lymphocyte transformation, macrophage phagocytic ability, E-rosette formation, Nk natural killer cell and plasma immunoglobulin content of a mouse. 7. Enhancing physical strength and relieving fatigue. The soybean glycopeptide can obviously increase the content of liver glycogen and muscle glycogen in the animal body, and has obvious physical enhancement effect. 8. Reducing blood sugar, and preventing and treating diabetes. The soybean glycopeptide can slowly inhibit the alpha-glucosidase on intestinal microvilli from decomposing glucose in a glucose donor, thereby achieving the effects of reducing blood sugar and assisting in preventing and treating diabetes. 9. Regulating intestinal function, and preventing and treating constipation. The oligosaccharide in the soybean glycopeptide is not absorbed by human body, but can promote proliferation and growth of Bacillus bifidus in large intestine, secrete health promoting vitamins and microelements, inhibit proliferation of harmful bacteria and secretion of harmful substances, increase large intestine peristalsis, and promote defecation. Although both soy oligosaccharides and soy oligopeptides have several functions as described above, the combination of the two is more effective than the single use, especially in improving blood regulation.
Resistant dextrin: the resistant dextrin is processed by starch, is a low-calorie glucan which is prepared by extracting and refining indigestible components of baked dextrin by using industrial technology, and belongs to low-molecular water-soluble dietary fiber. As a low-calorie soluble food raw material, has wide development prospect in the food industry.
Maltodextrin, 2: digestion: using the equation published by Roberfroid (1999), the caloric value of resistant dextrins is 7.1 kJ per gram (1.7 kcal per gram), which is consistent with what is determined clinically in healthy young people (Vermorel et al, 2004) and also with what is recognized as the caloric value of soluble dietary fibers (Livesey, 1992). This value can be used in europe to determine the energy content of food (Coussement, 2001). Resistant dextrins, unlike standard starches, are in fact partially hydrolysed in the upper part of the digestive tract (Vermorel et al, 2004) with only 15% being enzymatically digested in the small intestine and the remainder entering the large intestine, 75% of the initial amount being slowly and gradually fermented in the large intestine and 10% being excreted outside the body (Van den Heuvel et al, 2004). Blood sugar function: during the last decades, numerous definitions of prebiotic products have emerged, which differ more or less subtly. The well-known pro-biological products currently in use include various types of oligosaccharides (e.g., insulin, fructo-oligosaccharides, and galacto-oligosaccharides), among others (Alexiou and Franck, 2008), and although there is a concern about excessive gas production from the intestinal tract when taken in large quantities, the history of their safe use has been long. However, new compounds claiming to have prebiotic properties are also emerging, requiring a broader definition of prebiotic failure to reflect the latest advances in the micro-ecology of the human microbiota. The definition of prebiotic products was recently modified by the international food and agriculture organization to 'inactive food components that could produce health benefits to the host related to microbiota regulation taking all these factors into account' (international food and agriculture organization, 2007). With some emphasis on the physiological effects observed after ingestion of prebiotic products, resistant dextrins were studied according to a definition of prebiotic products (Woods & Gorbach 2001) which states that prebiotic products are characterized by an increase in ' beneficial bacteria ' and/or a decrease in ' harmful bacteria ', a decrease in intestinal pH, the production of SCFAs and a change in bacterial enzyme concentration '. Studies have shown that resistant dextrins exhibit all of these prebiotic effects through colonic fermentation. These different results are from a number of studies, in vitro, in animal (rat) and in human (Van den Heuvel et al, 2005; Lefranc-Millot et al, 2006b; Pasman et al, 2006). These fermentations are beneficial to colonic cells in the epithelium of the digestive tract, causing an increase in beneficial glycolytic flora, lowering colonic pH, and thereby reducing potentially pathogenic flora (e.g., 15 grams of resistant dextrin taken daily, with a significant decrease in the number of clostridium perfringens in human stools after 14 days, P < 0.05). SCFAs produced by the fermentation of carbohydrates in the large intestine are also involved in the daily energy supply of the body, as they can be used as metabolic fuels. Since this fermentation does not occur suddenly, but rather progresses gradually in the large intestine, the continued production of SCFAs, coupled with the release of partial digestion in the small intestine initially, makes resistant dextrins a long-lasting source of calories. This slow and gradual fermentation is in contrast to some other soluble fibers, which ferment rapidly and may cause digestive discomfort such as bloating and diarrhea. The claimed good tolerability of resistant dextrins with a threshold of 45 grams per day, without any symptoms of digestive discomfort, and no diarrhea occurring at a dose of 100 grams per day, was achieved when amounts are administered which are indicated to provide nutritional benefits (Van den Heuvel et al, 2004; Vermorel et al, 2004; Lefranc-Millot et al, 2006b; Pasman et al, 2006). In china, resistant dextrins have been identified as prebiotic products by the "public nutrition improvement micro-ecological program" in 2008. The aim is to increase the use of prebiotic preparations in china to improve the gut flora imbalance which has been identified as a key factor for sub-health.
Inulin: inulin is a reserve polysaccharide in plants, mainly comes from plants, and has been found in 36000 kinds, including 11 families of dicotyledonous plants such as Compositae, Campanulaceae and Gentianaceae, and 11 families of monocotyledonous plants such as Liliaceae and gramineae. For example, inulin is abundant in Jerusalem artichoke, tubers of chicory, root tuber of Paeonia suffruticosa (Dali chrysanthemum), and roots of Cirsium japonicum, wherein inulin content of Jerusalem artichoke is the highest. The inulin molecules are polymerized by 31 beta-D-fructofuranose and 1-2 pyranoinulin residues, and the fructose residues can be connected through beta-2, 1-bonds. The inulin is linear straight-chain polysaccharide formed by linking D-fructose through beta (1 → 2) glycosidic bonds, the tail end of the linear straight-chain polysaccharide is usually provided with a glucose residue, the polymerization Degree (DP) is 2-60, wherein inulin with the average polymerization degree DP less than or equal to 9 is also called short-chain inulin, and inulin extracted from natural plants simultaneously contains long chains and short chains. Inulin has the formula GFn, wherein G represents the terminal glucose unit, F represents the fructose molecule, and n represents the number of fructose units.
1. Controlling blood lipids
The intake of inulin can effectively reduce serum Total Cholesterol (TC) and low density lipoprotein cholesterol (LDL-C), increase high density lipoprotein/low density lipoprotein ratio, and improve blood lipid condition. Hidaka et al reported that in elderly patients 50-90 years of age, levels of triglycerides and total cholesterol in the blood decreased after two weeks by daily intake of 8g of short-chain dietary fiber. Yamashita et al consumed 8g of inulin for two weeks in 18 diabetic patients, resulting in a 7.9% reduction in total cholesterol, but no change in HDL-cholesterol. The above parameters were unchanged for the control group that had been fed the diet. Brighenti et al observed that in 12 healthy young men, a total cholesterol reduction of 8.2% and a substantial triglyceride reduction of 26.5% was achieved by adding 9g of inulin to a daily breakfast cereal for 4 weeks.
Many dietary fibers reduce blood lipid levels by absorbing intestinal fat to form fat-fiber complexes that are carried out with the stool. Furthermore, inulin ferments itself to short chain fatty acids and lactate, which are regulators of liver metabolism, before it ends up in the intestine. Short chain fatty acids (acetate and propionate) are used as fuel in the blood, and propionate inhibits cholesterol synthesis.
2. Reducing blood sugar
Inulin is a carbohydrate that does not cause an increase in urine glucose. It is not hydrolyzed to monosaccharides in the upper part of the intestinal tract and thus does not raise blood sugar levels and insulin content. Studies today show that the reduction in fasting plasma glucose is a result of short chain fatty acids produced by fermentation of fructooligosaccharides in the colon.
3. Promoting mineral absorption
The inulin can greatly improve the absorption of minerals such as Ca2+, Mg2+, Zn2+, Cu2+, Fe2 +', and the like. It was reported that adolescents eating 8 g/d (long and short chain inulin-type fructans) for 8 weeks and 1 year, respectively, found that Ca absorption was significantly improved and bone mineral content and density of the body were significantly increased.
The main mechanism of inulin for promoting mineral element absorption is 1) short chain fat generated by inulin fermentation in colon makes crypt on mucosa become shallow, crypt cells increase to increase absorption area, and cecal vein is developed. 2) The acid generated by fermentation lowers the pH value of colon, so that the solubility and the bioavailability of a plurality of mineral substances are improved, in particular, short-chain fatty acid can stimulate the growth of colon mucosal cells and improve the absorption capacity of intestinal mucosa, and 3) inulin can promote some microorganisms to secrete phytase, and the phytase can release metal ions chelated with phytic acid to promote the absorption of the metal ions. 4) Some organic acids generated by fermentation can be chelated with metal ions to promote the absorption of the metal ions.
4. Regulating intestinal microbial flora, improving intestinal health, and preventing constipation
Inulin is a natural water-soluble dietary fiber, hardly hydrolyzed and digested by gastric acid, and is utilized only in the colon by beneficial microorganisms, thereby improving the intestinal environment. It has been found that the degree of proliferation of bifidobacteria depends on the number of primary bifidobacteria in the large intestine of humans, and that the effect of proliferation is significant when inulin is used when the number of primary bifidobacteria is reduced, and not significant when inulin is used when the number of primary bifidobacteria is increased. Secondly, after the inulin is ingested, the gastrointestinal peristalsis can be enhanced, the gastrointestinal function can be improved, the digestion and the appetite can be increased, and the organism immunity can be improved.
5. Inhibiting the formation of toxic fermentation product, protecting liver, and preventing colon cancer
The food reaches colon after being digested and absorbed, under the action of intestinal saprophytic bacteria (Escherichia coli, Bacteroides and the like), a plurality of toxic metabolites (such as ammonia, nitrosamine, phenol, cresol, secondary bile acid and the like) can be generated, and short-chain fatty acid generated by fermenting inulin in the colon can lower the pH of the colon, inhibit the growth of saprophytic bacteria, reduce the generation of toxic products and reduce the stimulation of inulin to intestinal walls. As a series of metabolic activities of inulin can inhibit the generation of toxic substances, increase defecation frequency and weight, increase fecal acidity, accelerate the excretion of carcinogen, generate short-chain fatty acid with anticancer effect, and is beneficial to preventing colon cancer.
6. The dietary fiber for preventing constipation and treating obesity can reduce the retention time of food in stomach and intestine, increase the amount of excrement, and effectively treat constipation. The weight reducing effect is to increase the viscosity of the contents and reduce the speed of food entering the small intestine from the stomach, thereby reducing hunger sensation and food intake.
7. The inulin contains a small amount of 2-9 fructo-oligosaccharide, and research shows that the fructo-oligosaccharide can increase the expression of brain nerve cell trophic factors, has good protection effect on corticosterone-induced neuron damage, and has good antidepressant effect.
Inulin for reducing blood sugar and reducing blood sugar concentration
1. Blood glucose level decrease: eating inulin or drinking inulin concentrate can lower blood sugar value immediately. Many people perceive a significant decrease in blood glucose in a short period of time. The following are reports of 6 patients who eat inulin or drink inulin concentrate for 10 consecutive days:
(Note: the unit of blood glucose is mg/dl, which refers to the glucose content per deciliter. normal persons have 80-100 mg of glucose per deciliter on an empty stomach, hypoglycemia below this standard, and hyperglycemia above this standard.)
2. Alleviating the symptoms of diabetes: in the past, people live to eat the inulin powder and have no special effect on treating diabetes mellitus. After investigation by related people, the inulin powder is used for a long time to react, namely, the phenomena of body weakness are avoided, the feeling of thirst is not avoided, the times of going to the toilet at night are reduced, the eyes become bright, and the like.
Secondly, the digestion and defecation functions are enhanced, and the traditional Chinese medicine composition has a special effect on treating constipation: many people who eat inulin obviously feel that the gastrointestinal function is enhanced and the stool is unblocked. Simultaneously, after the inulin is taken, the intestinal peristalsis capability can be enhanced, odor gas is discharged, and the intestinal health is recovered, and particularly, the inulin has good prevention and treatment effects on some habitual constipation and intractable constipation.
Sixthly, improving the vascular disorder: inulin has a very significant effect on improving vascular disorders. There are many reports of inulin reducing blood lipids and cholesterol.
Seventhly, weight losing efficacy: inulin can promote the absorption of vitamins and microelements by regulating the movement of intestines and stomach, so that the health is realized, the physical strength is sufficient, the consumption of internal energy is promoted in turn, and the purpose of losing weight is achieved. On the other hand, after inulin is ingested, blood sugar is reduced, blood sugar does not rise, insulin of pancreatic islets is not secreted, insulin is not secreted, glucose and the like are not stored in cells, so that the body is not fat. On the basis, when some exercises are properly done, part of fat can be burnt, and the purpose of slimming is achieved.
Nine, low or no energy: inulin oligosaccharide is difficult or not digested and absorbed by human body, and the provided energy value is very low or not at all, so that the inulin oligosaccharide can play a role in low-energy food, furthest meets the requirements of people who like sweetmeats and worry fatness, and can be eaten by diabetes patients, fat patients and hypoglycemia patients.
Tenth, rapidly increasing the number of bifidobacteria in intestinal tracts: promotes the proliferation of bifidobacteria in the colon at a rate 40-fold increase. The adult ingests 10g inulin oligosaccharide per day, and the number of bifidobacteria per gram of feces increases by 20% after one week. The intake of 10g inulin oligosaccharide per day reduced the production of 44.6% toxic fermentation products and 40.9% harmful bacterial enzymes within 3 weeks.
Eleven, improvement of skin itch associated with diabetic patients: the obvious improvement of skin caused by using inulin is the change of improving and eliminating skin itch of diabetics, especially for old people and women, and the taking time of inulin is about 10 days, which is almost a special effect of eliminating diseases by medicine.
Twelve improving effects on mild and moderate depression and anxiety: the 2-9 fructo-oligosaccharide in inulin can increase the expression of brain nerve cell trophic factor, has good protection effect on corticosterone-induced neuron damage, and has good effect on mild and moderate depression, so the fructo-oligosaccharide can affect the concentration of NE and 5-HT in the center, and has good effect on mild and moderate depression and anxiety.
Fructo-oligosaccharide: also called fructo-oligosaccharide, is a mixture of kestose, nystose and the like, which are generated by combining 1-3 fructosyl groups with the fructosyl groups in sucrose through beta (2-1) glycosidic bonds. About 60-70 g of inulin, which is a fructan linked by linear beta-2, 1-glycosidic chains ending with a saccharose group, is present in 100 g of dry jerusalem artichoke. Therefore, the jerusalem artichoke powder is used as a raw material, hydrolyzed by the endoenzyme inulinase and refined to finally obtain the fructo-oligosaccharide syrup. Besides the physicochemical properties of general functional oligosaccharides, the fructo-oligosaccharide has the most remarkable physiological characteristics that the fructo-oligosaccharide can obviously improve the microbial population ratio in the intestinal tract, is an activated proliferation factor of bifidobacterium in the intestine, can reduce and inhibit the generation of putrefactive substances in the intestine, inhibits the growth of harmful bacteria and regulates the balance in the intestinal tract; can promote the absorption and utilization of trace elements of iron and calcium to prevent osteoporosis; can reduce liver toxin, can generate anticancer organic acid in intestines, and has obvious cancer prevention function; and the taste is pure, fragrant, sweet and delicious, and has the fragrance similar to fat and the smooth and greasy feeling of mouth feel. In recent years, fructo-oligosaccharide products are in the health-care product markets of popular days, Europe, America and the like. The syrup is colorless or light yellow, transparent viscous liquid, has fructo-oligosaccharide faint scent, and has soft and refreshing sweet taste, no foreign impurities. The powdered sugar is white or yellowish amorphous powder (white or yellowish amorphous granule), has soft and refreshing sweet taste, has fructo-oligosaccharide fragrance, and has no foreign impurities. The efficacy is as follows: 1. the low heat value, because the fructo-oligosaccharide can not be directly digested and absorbed by human body, and can only be absorbed and utilized by intestinal bacteria, the heat value is low, the obesity can not be caused, and the weight-reducing effect can be indirectly realized. It is also a good sweetener for diabetic patients. 2. It has dental caries preventing effect because it cannot be used by oral bacteria (such as Streptococcus mutans Smutans). 3. Has the function of proliferating beneficial bacteria in the intestinal tract. The fructo-oligosaccharide has selective proliferation effect on beneficial bacteria such as Bifidobacterium, Lactobacillus, etc. in intestinal tract, so that beneficial bacteria have advantages in intestinal tract, inhibit growth of harmful bacteria, reduce formation of toxic substances (such as endotoxin, ammonia, etc.), and protect intestinal mucosa cell and liver, thereby preventing pathological intestinal cancer and enhancing immunity. 4. Can reduce the content of cholesterol and triglyceride in serum. 5. Promoting nutrient absorption, especially calcium absorption. 6. Can be used for preventing and treating diarrhea and constipation.
Linseed oil microcapsule powder: the sum of the contents of crude protein, fat and total sugar in flaxseed reaches 84.07%. The linseed protein has complete amino acid types, and the essential amino acid content is as high as 5.16 percent, so the linseed protein is a plant protein with higher nutritional value. The content of alpha-linolenic acid in linseed oil is 53%, the alpha-linolenic acid is an essential fatty acid for human bodies, can be converted into eicosapentaenoic acid and docosahexaenoic acid in the human bodies, and is an effective active ingredient in fish oil. Alpha-linolenic acid has the functions of resisting tumor, resisting thrombus, reducing blood fat, nourishing brain cells, regulating vegetative nerves and the like, and is concerned more. The linseed contains a large amount of polysaccharide, and the polysaccharide has the effects of resisting tumor, virus, thrombus and blood fat.
Through research and clinical experiments, the linseed oil is proved to have the following functions:
1. the skin is tender and bright: improve the fat content of the skin, ensure that the skin is more tender, moist, soft and elastic, ensure the skin to breathe and perspire normally and relieve various skin problems.
2. Weight loss can consume excessive fat in the body, and is a healthy weight loss method.
3. Improving the female premenstrual syndrome: there are many examples of premenstrual syndrome in women, such as dysmenorrhea, etc., and the symptoms disappear completely after eating fresh linseed oil every day, and it is necessary to mix vitamins and minerals.
4. And (3) improving the compressive resistance: omega 3 can reduce the influence of harmful biochemical substances generated when the body is stressed, stabilize mood, maintain calm state, and reduce melancholia and insomnia.
5. And (3) reducing the allergic reaction: omega 3 helps to alleviate allergic reactions, but as the whole body needs to be reorganized, it takes a long time to completely eliminate allergy, and comprehensive nutritional assistance is needed.
6. Relief of asthma: after eating for several days, the asthma attack can be obviously relieved.
7. Improving arthritis: experiments prove that omega 3 has great effect on treating and preventing arthritis. After 60% of the rheumatoid arthritis patients received omega 3 and 6 fatty acid treatment, the non-steroidal anti-inflammatory drugs can be completely stopped, and the non-steroidal anti-inflammatory drugs can be halved for another 20%.
8. Improving organ tissue inflammation: omega 3 is useful in preventing inflammation of organs and tissues including meningitis, tendinitis, tonsillitis, gastritis, ileitis, colitis, arteritis, phlebitis, prostate inflammation, nephritis, splenitis, hepatitis, pancreatitis, otitis, and tinea and sore.
9. Reducing cholesterol: omega 3 can reduce high cholesterol in blood by 25% and triglyceride by 65%, and convert excessive low density cholesterol (LDL) into cholic acid to be discharged out of body.
10. Reducing the heart load: can reduce hypertension, reduce blood lipid content, increase unsaturated fatty acid level, improve blood concentration, reduce blood viscosity, maintain blood fluidity, and prevent blood vessel obstruction and related diseases. In addition, it can prevent blood coagulation, and prevent stroke (heart and cerebral artery blockage), heart disease (heart artery blockage), pulmonary artery embolism (pulmonary artery blockage) and blood vessel surface diseases (jaundice).
11. Improving water retention: helping the kidneys to remove sodium and water. Stagnant water typically occurs in swollen ankles, overweight in certain situations, premenstrual syndrome, late stage cancer, cardiovascular disease, and the like.
12. Improving renal function: omega 3 regulates Prostaglandin (Prostaglandin), promotes the secretion of liver, pancreas and spleen, and makes the metabolism work normally.
13. Improving constipation: improving intestinal function, increasing absorption capacity, increasing intestinal peristalsis capacity, normalizing defecation, and relieving constipation.
14. Promoting cell health: improve the water content and elasticity of cell membrane, increase the functions of cell respiration and nutrient exchange, strengthen the capability of repairing and healing cells, keep the cells healthy and reduce the chance of cancer.
15. Promoting flexibility of brain tendons: increase brain transmission medium (neuron), strengthen brain activity function, make brain operate more effectively, learn thinking ability better.
16. Energetic: balance and improve the blood sugar level of the body, so that the body is more active. Can also increase the endurance of muscles and can make the fatigue muscles recover more quickly after sports.
Corn oligopeptide powder: it is produced by using corn protein powder as raw material and through the processes of size mixing, protease enzymolysis, separation, filtration, spray drying and the like. Is a new resource product, and can be used for lowering blood pressure, relieving hangover, protecting liver, and enhancing immunity.
Black fungus extract: the Auricularia extract is rich in Auricularia polysaccharide, and comprises monosaccharide such as L-fucose, L-arabinose, D-xylose, D-mannose, D-glucose and glucuronic acid. The agaric is sweet and mild in nature and is nontoxic. Has effects in invigorating qi and blood, cooling blood, stopping bleeding, moistening lung, benefiting stomach, moistening dryness, promoting intestinal function, relaxing muscles and tendons, activating collateral flow, and strengthening body constitution. Can be used for treating blood deficiency, qi deficiency, cough due to lung deficiency, and puerperal asthenia.
The black fungus contains eight amino acids and vitamins necessary for human body, and has high nutritive value and certain medicinal value. The black fungus contains rich colloid, has good moistening effect on human digestive system, and has effects of clearing esophagus, cleaning intestine, moistening lung, reducing blood clot, relieving coronary artery porridge sclerosis, and reducing thrombosis. The polysaccharide substance in the black fungus has certain effect on preventing human body tumors, and is a necessary health food for workers in the textile industry, the hair cutting industry and the mine under high-dust operation conditions.
The polysaccharide has the following effects: the fruiting body of Auricularia contains acidic mucopolysaccharide, and has effects of lowering blood sugar, reducing blood lipid, resisting aging, ulcer, radiation and thrombosis, improving immunity, and enhancing disease resistance.
Kudzu root extract: the radix Puerariae extract contains multiple flavonoids, and contains daidzein, daidzin, puerarin, and puerarin-7-xyloside as main active ingredients; has effects in dilating blood vessel and improving blood circulation; reducing myocardial oxygen consumption, inhibiting cancer cells; increase coronary flow, regulate blood microcirculation; treating sudden deafness at various ages; reduce the risk of cardiovascular and cerebrovascular diseases.
And (3) hawthorn extract: dried mature fruit (containing kernel) extract of Crataegus Pinnatifida Bge of Rosaceae (Rosaceae) or Crataegus pinnatifida Bge of Crataegus or Crataegus pinnatifida B ge of Crataegus. The pharmacological action is as follows: (1) the hawthorn has the effects of increasing myocardial contraction force, increasing cardiac output and slowing down heart rhythm.
(2) Has effects in increasing coronary blood flow, and reducing myocardial oxygen consumption and myocardial oxygen utilization rate. (3) The hawthorn fruit has certain effect of increasing the myocardial trophism blood flow, and the hawthorn fruit has the effect of increasing the myocardial trophism blood flow, and can be related to the expansion of coronary vascular beds and the improvement of coronary circulation.
(4) The hawthorn has a protective effect on acute myocardial ischemia caused by isoproterenol sulfate in guinea pigs. The fructus crataegi extract has effects of preventing or relieving myocardial ischemia or necrosis caused by isoproterenol.
(5) The blood pressure lowering effect is that the hawthorn ethanol extract has a relatively long-lasting blood pressure lowering effect.
(6) The blood fat reducing function is that different extracted parts of hawthorn have certain blood fat reducing function on various high fat models caused by different animals, and can antagonize the increase of serum cholesterol and triglyceride caused by high fat feed.
The tartary buckwheat extract: the tartary buckwheat is a very few medical and edible dual-purpose crop in nature, integrates seven nutrients, is not a medicine, is not a health-care product, and is a food which can be eaten as rice.
According to records in Bencao gang mu, the tartary buckwheat has bitter taste and moderate and cold nature, can strengthen intestines and stomach, tonify qi, continue spirit, benefit ears and eyes and refine five internal organs and dregs, and has the effects of soothing nerves, activating qi and blood, reducing qi, widening intestines, clearing heat, swelling and pain, removing accumulation and removing stagnation, clearing intestines, relaxing bowels, relieving cough, relieving asthma, resisting inflammation, resisting allergy, strengthening heart, losing weight, beautifying and the like in records in Qianjin Yao Fang, Chinese medicine dictionary and related documents. The tartary buckwheat is tartary buckwheat, namely buckwheat leaf seven, wild buckwheat, perennial buckwheat, spinach wheat, black wheat and buckwheat. The nutrition value of the buckwheat is much higher than that of the common buckwheat. Especially, the content of bioflavonoid is 13.5 times of that of buckwheat.
The tartary buckwheat is a natural functional food integrating nutrition, health care and medical treatment. Records about disease prevention and treatment of tartary buckwheat in ancient books of China.
The Qifol Yao Shu (national treasures) has the effect that the bird catching birds with birds or birds sweat through the cake of the flour soup and powder, even though the bird catching birds with birds or birds still catch the cold for decades.
The book of materia Medica in the picture is recorded as 'excessiveness to the intestines and stomach and energy benefiting'. The book Ben Cao Zu (materia Medica) has the discussions of descending qi, relieving intestinal stasis, eliminating heat, swelling and wind pain, removing white turbidity, blood stagnation, spleen accumulation and diarrhea. The bitter buckwheat is recorded to have bitter, mild and cold nature, and has the effects of benefiting strength, keeping spirit, benefiting ears and eyes, descending qi, widening intestines and invigorating stomach.
The famous plant picture examination calls buckwheat as the property food retention removing, commonly called Jing Chang Cao. Tartary buckwheat has the functions of reducing blood pressure, blood sugar, blood fat, microcirculation and the like, and is also called as 'three-lowering' food.
And (3) reducing blood sugar: an investigation by the public health academy of Harbin medical university shows that the blood sugar level and the prevalence of diabetes of people in the buckwheat area as staple food are obviously lower than those of people in the buckwheat area without eating the buckwheat. Wherein, the detection rate of hyperglycemia of residents taking the buckwheat as the staple food (namely the blood sugar level higher than the normal value) is 1.6 percent, while the detection rate of hyperglycemia of the residents taking the buckwheat as the staple food is 7.33 percent, and the detection rate of hyperglycemia of the residents taking the buckwheat as the staple food is about 4 times higher than that of the residents taking the buckwheat as the staple food. The prevalence rate of diabetes of the staple food buckwheat and the region without eating the buckwheat is about 1 time, the former is 1.88%, and the latter is 3.84%, and the conclusion suggests that the buckwheat is more suitable for the dining table of common people as a coarse cereal crop for effectively reducing the occurrence of diabetes.
And (3) reducing blood fat: animal experiments show that the tartary buckwheat flavonoid can obviously reduce the triglyceride level of a hyperlipoidemia mouse and the cholesterol and triglyceride level of a hyperlipoidemia rat, but does not reduce the high-density lipoprotein level of the hyperlipoidemia mouse and the hyperlipoidemia rat, so the tartary buckwheat flavonoid has the function of reducing blood fat. In addition, the raw tartary buckwheat can be used as tea after being properly baked and processed, but the baking process of the tartary buckwheat has high requirements, and the tartary buckwheat is easily fried and burnt or the fried heat cannot be obtained, so that the effective components of the tartary buckwheat are damaged, and the taste and the leaching rate of rutin are influenced. The reason is that quercetin and the like contained in the tartary buckwheat bioflavonoid can reduce the content of triglyceride and total cholesterol and reduce the atherosclerosis index.
Effect on myocardium: the main component of the bioflavonoid rich in the tartary buckwheat is rutin, also called VP, and the main effects of the bioflavonoid are softening blood vessels, improving microcirculation, clearing away heat and toxic materials, promoting blood circulation to remove blood stasis, drawing out toxin and promoting granulation, tonifying qi and refreshing, and reducing blood sugar and urine sugar. The content of bioflavonoids in the diet of 805 old men was measured by Rooibos Hetuogg in the Netherlands, and it was found that the risk of death due to coronary heart disease was reduced by 50% in the group in which bioflavonoids were ingested at a daily dose of not less than 30 mg compared to the group in which bioflavonoids were ingested at a daily dose of not more than 19 mg. Magnesium has good regulating effect on cardiac activity, and can slow down cardiac rhythm and cardiac excitation conduction, increase myocardial blood supply, and facilitate diastole and rest. The magnesium content of the tartary buckwheat is more than 11 times of that of the wheat flour.
Effect on blood vessels: the tartary buckwheat bioflavonoid has various physiological functions, wherein quercetin, morin and the like can improve the contraction and relaxation functions of vascular smooth muscle of an organism, and rutin has the functions of expanding blood vessels, maintaining the resistance of capillary vessels, reducing the permeability and brittleness of the capillary vessels, promoting cell proliferation, preventing blood cell agglutination, reducing blood fat, expanding coronary arteries, enhancing the blood flow of the coronary arteries and the like. The rich vitamins in buckwheat flour have the function of reducing blood fat and cholesterol of human bodies, and are important auxiliary food (medicine) for treating hypertension and cardiovascular diseases. Some microelements (such as magnesium, iron, copper, potassium, etc.) contained in buckwheat flour have effect of protecting cardiovascular system.
Antibacterial and antiviral effects: research proves that quercetin, morin and kaempferol which are rich in the tartary buckwheat bioflavonoid have bacteriostatic and antiviral effects. The clinical application of the flavone has the peculiar curative effects of removing putrefaction, promoting granulation, diminishing inflammation and easing pain on ulcer caused by various reasons.
Effect of scavenging free radicals: free radicals are the source of crime for cancer, aging, cardiovascular and cerebrovascular degenerative diseases. Because the flavonoids of tartary buckwheat are easily oxidized, the flavonoids of tartary buckwheat have the function of scavenging free radicals. The molecular structure of the buckwheat bioflavonoid conforms to the effective phenolic hydroxyl theory, has extremely strong free radical scavenging capacity, has 5 hydroxyl groups, can be sufficiently used as a hydrogen donor to reduce the free radicals, thereby playing the role of scavenging the free radicals and achieving the purposes of preventing aging, resisting cancer and resisting cardiovascular and cerebrovascular diseases. The tartary buckwheat bioflavonoid has a certain curative effect on acute and chronic hepatitis, cirrhosis, fatty liver and toxic liver injury caused by galactosamine, CCl4 and the like.
Research shows that the tartary buckwheat bioflavonoid has an obvious inhibiting effect on the increase of the content of malondialdehyde (MDA liver lipid peroxidation final product) in liver caused by CCl4, can reduce the consumption of Glutathione (GSH) caused by liver injury, can protect the integrity of cell structure, and can prevent soluble enzymes such as transaminase in liver cells from leaking from the cells to increase the activity. The liver protection mechanism of the tartary buckwheat bioflavonoid finally lies in the effects of oxidation resistance and free radical resistance.
Cranberry fruit powder: the cranberry juice can effectively inhibit helicobacter pylori and resist bacterial gastric ulcer, has strong antioxidation effect, can reduce low-density cholesterol and triglyceride, and is particularly suitable for women to eat. The product can be taken more than 350 ml daily, and is helpful for preventing urinary tract infection and cystitis. Cranberry is a red berry produced mainly in North America and the like, and is rich in antioxidant polyphenols. Previous researches show that when cranberries are properly eaten, the cranberries have the effects of enhancing the immune effect and preventing urinary system infection.
(1) Can inhibit the growth and reproduction of various pathogenic bacteria, prevent the adhesion of these pathogenic bacteria to cells in vivo (such as epithelial cells of urinary tract), prevent and control female urinary tract infection, and inhibit helicobacter pylori infection;
(2) helping to maintain the integrity of the bladder wall and maintain the normal pH of the urethra.
Reducing the incidence of gastric ulcer and gastric cancer: cranberry contains a specific compound, condensed tannic acid, and in addition to being generally recognized as having a function of preventing urinary tract infection, cranberry helps to inhibit the adhesion of helicobacter pylori to the intestines and stomach. Helicobacter pylori is a leading cause of gastric ulcer and even gastric cancer.
Reducing cardiovascular aging lesions: a study report published by researchers at 09/20/2012 in the united states department of agriculture at a medical conference held in washington states that tests have shown that healthy adults can moderately lower blood pressure if they regularly drink low-calorie cranberry juice.
A total of 56 healthy adults, 51 years of average age, were enrolled in this randomized trial by the american department of agriculture, one group drinking about 227 grams of low calorie cranberry juice each day at breakfast and supper, and another group drinking a placebo of similar color and taste. All participants were provided with additional diets by the research institution so that their weights remained stable, thereby controlling the error to a minimum. After 8 weeks of observation in volunteers, the investigators found that people drinking cranberry juice had a diastolic blood pressure drop from the initial average of 74 mmhg to 71 mmhg and a systolic blood pressure drop from the initial average of 122 mmhg to 119 mmhg. The placebo group did not change.
Janit Norwalk, leading the study, said that the blood pressure lowering efficacy of cranberry juice may result from antioxidants enriched in this juice, and cranberry juice is a good choice if it is desired to regulate blood pressure by diet.
Anti-aging, preventing senile dementia: cranberry has a very strong resistance to free radical species, bioflavonoid, and its content is higher than that of the crown of the generally common 20 kinds of vegetables and fruits. The bioflavonoid can effectively prevent senile dementia.
Beautifying and maintaining young and healthy skin: the cranberry contains vitamin C, flavonoid and other antioxidant substances and abundant pectin, and has effects of caring skin, improving constipation, and promoting discharge of toxin and excessive fat.
Gamma-aminobutyric acid: gamma aminobutyric acid is an important inhibitory neurotransmitter in the central nervous system, is a naturally-occurring non-protein amino acid, has extremely important physiological functions, can promote the activation of the brain, strengthen the brain, improve intelligence, resist epilepsy, promote sleep, beautify and moisten the skin, delay the aging function of the brain, supplement the inhibitory neurotransmitter of a human body, and has good effect of reducing blood pressure. Promoting kidney function improvement and protection. Inhibiting fatty liver and obesity, and activating liver function. The daily supplement of trace gamma aminobutyric acid is beneficial to relieving the cardio-cerebral blood pressure, can promote the balance of amino acid metabolism in a human body and regulate the immune function. Gamma-aminobutyric acid belongs to strong nerve inhibitory amino acid and has the physiological effects of tranquilizing, hypnotizing, resisting convulsion and reducing blood pressure. It is an Inhibitory Neurotransmitter (Inhibitory Neurotransmitter) that inhibits the activity of animals and reduces energy consumption. Aminobutyric acid acts on GABA receptors in animal cells, the GABA receptors are chloride ion channels, the inhibition or excitability of GABA depends on the concentration of chloride ions inside and outside cell membranes, after the GABA receptors are activated, the chloride ion channels are opened, the permeability of the cell membranes to chloride ions can be increased, the chloride ions flow into nerve cells, the hyperpolarization of the cell membranes is caused, the excitation of nerve cell units is inhibited, and the exercise amount of animals is reduced. It reduces the energy consumption by reducing the involuntary movement of animals, thereby achieving the purpose of promoting the growth. The gamma-aminobutyric acid can promote the secretion of gastric juice and growth hormone of animals, thereby improving the growth speed and the feed intake; can stimulate the feeding center of animals, thereby increasing the feed intake.
D-ribose: d-ribose is a monosaccharide containing five carbon atoms, an extremely important aldopentose, and has α and β forms, and is mostly present in the form of pentosan or glycoside in the living body. Ribonucleotides
D-ribose is an important constituent of ribonucleic acid (RNA) which is a genetic substance in organisms, is positioned at a pivot position in the metabolism of nucleoside substances, proteins and fat, and has important physiological functions and wide application prospects. D-ribose, a natural component present in all cells in the organism, is closely related to the formation of adenosine and the regeneration of Adenosine Triphosphate (ATP), and is one of the most basic energy sources for life metabolism. Plays a key role in the metabolism of heart and collateral muscles and can promote the recovery of ischemic tissues and hypoxic tissues.
The nucleic acid medicine is an important means for treating virus, tumor and AIDS in human at present, and D-ribose is an important intermediate of many nucleic acid medicines and can be used for producing various medicines such as ribavirin, adenosine, thymidine, cytidine, fluoroadenosine, 2-methyladenosine, wiltatoxin, pyrazole toxin, ademetionine and the like. The heart and skeletal muscle of the human body synthesize ATP slowly by themselves, and D-ribose accelerates the synthesis of ATP in the heart and skeletal muscle, so that the heart and skeletal muscle are the organs and tissues most in need of D-ribose. One of the D-ribose magical effects is to improve cardiac ischemia and improve cardiac function: cardiac ischemia causes cardiac dysfunction and arrhythmia. Research proves that the oral administration of the D-ribose can promote the generation of ATP of myocardial cells, so that the functions of the myocardial cells are normal, thereby obviously improving the cardiac function, protecting the heart during ischemia, protecting the arrhythmia induced by the cardiac ischemia, obviously improving the original symptoms of asthma, frequent palpitation, chest distress and qi deficiency after moving, and greatly improving the life quality. The second magic of D-ribose is to enhance the energy of the body and relieve the aching pain of muscles: the direct cause of fatigue in humans is insufficient ATP production in muscle cells, which results in insufficient energy for muscle activity, and human fatigue. D-ribose is the starting molecule for the synthesis of ATP, an important starting material for the muscle synthesis of the energy substance ATP. Research proves that the supplement of D-ribose can improve the exercise capacity of human body, effectively resist fatigue and relieve muscle soreness.
L-arabinose: the L-arabinose has two main using functions in the aspects of food and medicine, namely, the L-arabinose can inhibit enzyme for hydrolyzing disaccharide, so that the increase of blood sugar caused by taking sucrose (decomposed into glucose and fructose and absorbed under the action of small intestine sucrase) is inhibited, and the L-arabinose is called as blood sugar reducing effect for inhibiting the hydrolysis of disaccharide for short. Secondly, because of the inhibition effect of the L-arabinose on disaccharide hydrolase, the sucrose which is not decomposed in the small intestine is decomposed by microorganisms in the large intestine to generate a large amount of organic acid which has the inhibition effect on the synthesis of fat by the liver, and the L-arabinose has the inhibition effect on the absorption of the sucrose in the small intestine, thereby reducing the generation of new fat in the body. The L-arabinose can be used together with sucrose or eaten independently. The sucrose is added in a proportion of 3.5%, which can inhibit the absorption of 60-70% sucrose by human body, and can reduce blood sugar after long-term use. The effect is the same when the L-arabinose is eaten independently.
Firstly, inhibiting metabolism and absorption: the most representative physiological role of L-arabinose is to selectively affect sucrase in the small intestine, thereby inhibiting sucrose absorption. It has been reported that addition of 3.5% L-arabinose to sucrose can suppress the absorption of 60-70% sucrose and also increase the blood glucose level by about 50% less.
Inhibiting blood sugar and fat: l-arabinose, a low calorie sugar, inhibits the elevation of blood sugar level caused by the intake of sucrose, and thus can inhibit obesity, prevent and treat diseases associated with hyperglycemia.
Thirdly, constipation prevention: according to the results of the Japanese study, it was found that the number of defecation times per week was significantly increased when sucrose supplemented with 3% L-arabinose was added to a drink such as black tea for continuous administration to women who had a tendency to constipation. And experiments of starch corporation prove that the intake of sucrose with 5 percent of arabinose can effectively promote the growth of Bifidobacterium (Bifidobacterium). L-arabinose itself is a sugar which is difficult to be absorbed by the digestive tract, and a part which is not utilized in the body can be excreted from urine.
Fourth, effect on skeletal muscle composition: a2005 Japanese study demonstrated the effect of L-arabinose on energy expenditure and muscle fiber composition by feeding obese rats a 20% sucrose diet containing 20% sucrose (group C) and a 20% sucrose diet supplemented with 1.5% L-arabinose (group A) for 21 weeks. Abdominal adipose tissue weight and cell size were significantly increased in rats in group C, while adipose tissue weight and cell size were significantly suppressed in rats in group a. L-arabinose significantly inhibited the rise in blood glucose 2 hours after glucose administration. The percentage of energy consumed by fat in group a rats increased by 12.8% when evaluated by respiratory quotient. The number of type i fibers in the rectus abdominis muscle is significantly increased. Like other skeletal muscles, the rectus abdominis is also composed of type I and type II muscle fibers. These results suggest that L-arabinose has the efficacy of altering the skeletal muscle fiber component, affecting abdominal adipose tissue growth by governing glycolysis to sugar oxidation. This change in muscle fiber proportion may have an effect of ameliorating type 2 diabetes.
Taurine: 1.1 promoting the brain tissue and intelligence development of infants: the taurine has rich and widely distributed content in brain, can obviously promote the growth and development of nervous system and the proliferation and differentiation of cells, is dose-dependent, and plays an important role in the development process of brain nerve cells. Research shows that the taurine content in the brain of the premature infant is obviously lower than that of the term infant because the cysteine sulfinate dehydrogenase (CSAD) in the premature infant is not mature, and the synthesized taurine is not enough to meet the needs of the body and needs to be supplemented by breast milk. The taurine content in the breast milk is higher, and particularly the content in the breast milk is higher. If the supplement is insufficient, the growth and development of the children are slow and the intelligence development is retarded. Taurine is closely related to the development of central nerves, retinas and the like of infants and fetuses, and the lack of taurine is easily caused by long-term simple milk feeding.
Improving nerve conduction and visual function: cats and night owls are prey on mice mainly because mice contain abundant taurine, and their sharp vision can be maintained by eating too much taurine. Retinal dysfunction can occur in infants and young children if they are deficient in taurine. For a patient in long-term intravenous nutrition infusion, if taurine is not contained in the infusion, the electroretinogram of the patient can be changed, and the change can be corrected only by supplementing a large amount of taurine.
Prevention of cardiovascular diseases: taurine has effects of inhibiting blood platelet aggregation, reducing blood lipid, maintaining normal blood pressure and preventing arteriosclerosis in circulatory system, protecting cardiac muscle cells, resisting arrhythmia, reducing cholesterol content in blood, and treating heart failure.
Influence lipid absorption: taurine in the liver functions to combine with bile acids to form taurocholic acid, which is essential for the absorption of lipids in the digestive tract. Taurocholic acid can increase solubility of lipid and cholesterol, relieve bile obstruction, reduce cytotoxicity of free bile acid, inhibit formation of cholesterol calculus, and increase bile flow.
Improving endocrine state and enhancing human immunity: taurine has effects of promoting pituitary hormone secretion, activating pancreatic function, improving endocrine system state, regulating metabolism, enhancing immunity, and relieving fatigue.
Influence on sugar metabolism: taurine can be combined with insulin receptor to promote cell to take in and utilize glucose, accelerate glycolysis and reduce blood sugar concentration. Research shows that taurine has a certain hypoglycemic effect and does not depend on increasing the release of insulin. Regulation of cellular carbohydrate metabolism by taurine may be achieved by a post-receptor mechanism that relies primarily on interaction with the insulin receptor protein, rather than direct binding to the islet receptor.
Inhibiting the occurrence and the development of cataract: taurine has important functions of regulating the osmotic pressure of the crystal, resisting oxidation and the like, in the process of developing cataract, the sorbic acid content in the crystal lens is increased, the osmotic pressure of the crystal is increased, the concentration of taurine which is an important substance for regulating the osmotic pressure is obviously reduced, the anti-oxidation effect is weakened, and the protein in the crystal is excessively oxidized, so that the cataract is caused or aggravated. The supplement of taurine can inhibit the occurrence and development of cataract.
Improving the memory function: in animal experimental research on the relationship between taurine and brain development, the taurine can promote the learning and memory ability of white rats. The addition of appropriate amount of taurine can not only improve the learning and memory speed, but also improve the accuracy of learning and memory, and has certain effect on the anti-aging of the nervous system.
Maintaining normal reproductive function: normal reproductive function requires the use of taurine for maintenance. The data show that when the content of taurine in the cat feed is lower than 0.101%, the reproductive function is poor, the death rate, the abortion rate and the birth defect rate are increased, and the survival rate of young animals is reduced. When the content is more than 0.105%, the normal reproductive function can be maintained.
Other functions are as follows: taurine has obvious effect of preventing and treating iron deficiency anemia, can promote the absorption of intestinal tract to iron and increase the stability of erythrocyte membrane, is the growth promoting factor of bifidobacterium in human intestinal tract to optimize the structure of intestinal tract bacteria, has the functions of resisting oxidation and delaying senility, can promote acute hepatitis to restore normal, has the protection effect on carbon tetrachloride poisoning and can inhibit the rise of serum glutamic-pyruvic transaminase caused by carbon tetrachloride poisoning. The taurine has the effects of tranquilizing, relieving pain and diminishing inflammation, and can be used for preventing and treating cold injury, KCN poisoning and migraine.
The invention discloses a food therapy formula with antioxidant and bacteriostatic effects and capable of enhancing cardiovascular and cerebrovascular functions and human body immunity, which is a compound formula product, takes a plurality of soybean glycopeptides as main raw materials, is matched with a plurality of natural pure traditional Chinese medicine components for auxiliary use, not only can effectively reduce blood pressure and blood fat, but also can well improve human body immunity through antioxidant and bacteriostatic effects, plays the roles of effectively resisting aging and delaying aging time, and particularly can inhibit or reduce diseases caused by cardiovascular and cerebrovascular diseases through increasing the functions of the cardiovascular and cerebrovascular diseases. Is a general compound beverage product suitable for common drinking.
Claims (4)
1. A food therapy formula with antioxidant and antibacterial effects and capable of enhancing cardiovascular and cerebrovascular functions and human body immunity is characterized by comprising the following components:
the feed additive comprises soybean glycopeptide, resistant dextrin, maltodextrin, inulin, fructo-oligosaccharide, linseed oil microcapsule powder, corn oligopeptide powder, black fungus extract, kudzu root extract, hawthorn extract, tartary buckwheat extract, cranberry fruit powder, gamma-aminobutyric acid, D-ribose, L-arabinose, taurine, selenium-enriched yeast powder and multivitamin.
2. The food therapy formula with the functions of resisting oxidation and inhibiting bacteria and enhancing cardiovascular and cerebrovascular functions and human body immunity according to claim 1, which is characterized by comprising the following components in percentage by mass: 15-25 parts of soybean glycopeptide, 16-24 parts of resistant dextrin, 16-22 parts of maltodextrin, 12-18 parts of inulin, 8-12 parts of fructo-oligosaccharide, 3-4 parts of linseed oil microcapsule powder, 0.5-0.8 part of corn oligopeptide powder, 0.5-0.8 part of black fungus extract, 0.5-0.8 part of radix puerariae extract, 0.45-0.8 part of hawthorn extract, 0.4-0.8 part of tartary buckwheat extract, 3-7 parts of cranberry fruit powder, 0.1-0.3 part of gamma-aminobutyric acid, 0.2-0.4 part of D-ribose, 0.5-1 part of L-arabinose, 0.1 part of taurine, 0.1 part of selenium-enriched yeast and 0.39 part of compound vitamin, wherein the sum of the raw material components is one hundred percent.
3. The food therapy formula with the functions of resisting oxidation and inhibiting bacteria and enhancing cardiovascular and cerebrovascular functions and human body immunity according to claim 1, which is characterized by comprising the following components in percentage by mass: the weight percentages of the components are as follows: the feed additive comprises 20 parts of soybean glycopeptide, 20 parts of resistant dextrin, 20 parts of maltodextrin, 16 parts of inulin, 10 parts of fructo-oligosaccharide, 2.19 parts of linseed oil microcapsule powder, 0.78 part of corn oligopeptide powder, 0.78 part of black fungus extract, 0.78 part of kudzu root extract, 0.78 part of hawthorn extract, 0.78 part of tartary buckwheat extract, 6.33 parts of cranberry fruit powder, 0.2 part of gamma-aminobutyric acid, 0.39 part of D-ribose, 0.8 part of L-arabinose, 0.1 part of taurine, 0.1 part of selenium-enriched yeast and 0.39 part of vitamin complex, wherein the sum of the raw material components is one hundred percent.
4. A method for preparing a dietetic composition according to claims 1-3 having antioxidant and bacteriostatic effects and enhancing the cardiovascular and cerebrovascular and immune functions of the human body according to claim 1, wherein: preparing the raw materials according to the percentage, then pouring the purified water into a water cup, sequentially adding the raw materials into the cup, and uniformly stirring.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011408591.8A CN112690386A (en) | 2020-12-05 | 2020-12-05 | A dietetic composition with antioxidant and antibacterial effects and capable of enhancing cardiovascular and cerebrovascular and immunity |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011408591.8A CN112690386A (en) | 2020-12-05 | 2020-12-05 | A dietetic composition with antioxidant and antibacterial effects and capable of enhancing cardiovascular and cerebrovascular and immunity |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112690386A true CN112690386A (en) | 2021-04-23 |
Family
ID=75506298
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011408591.8A Pending CN112690386A (en) | 2020-12-05 | 2020-12-05 | A dietetic composition with antioxidant and antibacterial effects and capable of enhancing cardiovascular and cerebrovascular and immunity |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112690386A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114271502A (en) * | 2021-12-31 | 2022-04-05 | 青岛琛蓝健康产业集团有限公司 | Clam peptide compound for protecting cardiovascular system and kidney and application thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105661499A (en) * | 2016-01-07 | 2016-06-15 | 南京贝杉国际贸易有限公司 | Functional food capable of clearing blood fat, and preventing cardiovascular and cerebrovascular diseases and preparation method |
CN108523138A (en) * | 2017-03-02 | 2018-09-14 | 劲膳美食品股份有限公司 | A kind of hypoglycemic meal replacement powder |
CN109043555A (en) * | 2018-09-19 | 2018-12-21 | 山西康丰园生物工程有限公司 | A kind of Special food and preparation method thereof that hyperglycemic patients are edible |
-
2020
- 2020-12-05 CN CN202011408591.8A patent/CN112690386A/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105661499A (en) * | 2016-01-07 | 2016-06-15 | 南京贝杉国际贸易有限公司 | Functional food capable of clearing blood fat, and preventing cardiovascular and cerebrovascular diseases and preparation method |
CN108523138A (en) * | 2017-03-02 | 2018-09-14 | 劲膳美食品股份有限公司 | A kind of hypoglycemic meal replacement powder |
CN109043555A (en) * | 2018-09-19 | 2018-12-21 | 山西康丰园生物工程有限公司 | A kind of Special food and preparation method thereof that hyperglycemic patients are edible |
Non-Patent Citations (1)
Title |
---|
崔春: "《食物蛋白质控制酶解技术》", 30 June 2018, 中国轻工业出版社 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114271502A (en) * | 2021-12-31 | 2022-04-05 | 青岛琛蓝健康产业集团有限公司 | Clam peptide compound for protecting cardiovascular system and kidney and application thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104432084B (en) | A kind of conditioning powder and its production and use | |
CN106722963A (en) | A kind of vegetarian diet meal | |
CN101744170B (en) | Tartary buckwheat eight ingredient porridge suitable for patients with diabetes and preparing method thereof | |
CN101473953B (en) | Fabricated food for cleaning blood and expelling toxin as well as method for processing the same and application | |
CN104431741B (en) | Cereal conditioning porridge and making method and application thereof | |
CN104643250B (en) | It is a kind of can bidirectional modulation body weight improve inferior health solid beverage | |
CN106072573A (en) | A kind of it is applicable to the special dietary seafood that old aged muscle decay disease is edible | |
CN108719984B (en) | Meal replacement nutrition bar for gout population and preparation method thereof | |
CN102511869A (en) | Thickened red jujube ginger pulp | |
CN112741320A (en) | Weight-losing composition and preparation method and application thereof | |
CN105815514A (en) | Weight-losing quinoa milk tea | |
CN114128813A (en) | Beverage for relieving alcoholism and protecting liver and promoting vitality of liver and preparation method thereof | |
CN114711374A (en) | Composite nutrient powder of ferment fibre and its preparation method | |
CN105613882A (en) | Black barley hypoglycemic tea (milky tea) | |
CN112690386A (en) | A dietetic composition with antioxidant and antibacterial effects and capable of enhancing cardiovascular and cerebrovascular and immunity | |
CN107802770A (en) | Balance the Chinese medicine and health products of metabolic system radical cure early stage type II diabetes | |
KR102000170B1 (en) | Food compositions for reducing body fat and improving intestinal function | |
CN109820123A (en) | A kind of plant beverage and preparation method thereof improving microcirculation | |
CN115553406A (en) | Weight-reducing composition beverage for inhibiting absorption of fat and sugar substances and preparation method thereof | |
CN102048134A (en) | Five-material vegetable nutraceutical and preparation method thereof | |
CN101797049B (en) | Nutrient eight-treasure soup formula and preparation process thereof | |
CN113842452A (en) | Medicine composition for treating diabetes and preparation method thereof | |
CN106035686A (en) | Super chenopodium quinoa willd health-preservation plant milk | |
CN102511882A (en) | Red jujube thick syrup beneficial for improving growth and development | |
CN112843172A (en) | Chinese and western medicinal composition for improving human body function and discharging harmful toxin, and its preparation method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210423 |